Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05513742 · ClinicalTrials.gov registry record · Phase 2
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Compass Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT05513742 is a Phase 2 study that has completed, run by Compass Therapeutics. The registered enrollment target is 49 participants.
The verdict
NCT05513742, a Phase 2 study, has completed, sponsored by Compass Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.
Interventions
- DRUG CTX-009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2025-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05513742
The ClinicalTrials.gov registry entry for NCT05513742 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Compass Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTX-009 is the first listed.
NCT05513742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05513742 about?
NCT05513742 is a clinical study titled "A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer". This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional ...
What is the current status of trial NCT05513742?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2022-12-08. Estimated completion is 2025-05-15.
What interventions are being tested in trial NCT05513742?
The interventions under investigation include: CTX-009 (DRUG).
Who is sponsoring clinical trial NCT05513742?
This trial is sponsored by Compass Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.